Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2014, Vol. 41 Issue (5): 495-498    DOI: 10.12891/ceog17042014
Review | Next articles
Levonorgestrel-releasing intrauterine device used for dysmenorrhea: five-year literature review
A. Imai1, *(), K. Matsunami1, H. Takagi1, S. Ichigo1
1Department of Obstetrics and Gynecology, Matsunami General Hospital, Kasamatsu (Japan)
Download:  PDF(59KB)  ( 25 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Intrauterine devices (IUDs) provide highly effective, long-term, safe, reversible contraception, and are the most widely used reversible contraceptive method worldwide. The levonorgestrel-releasing IUD (LNG-IUD), originally designed for long-term contraceptives, is now recognized to provide non-contraceptive health benefits. These include severe dysmenorrhea and/or heavy menstrual bleeding associated with uterine myoma, endometriosis, and adenomyosis. This report aims to review the last five-year literature on the efficacy and safety of the LNG-IUD in women with dysmenorrhea. Dysmenorrhea has been reported to decrease in all women. LNGIUD seems to be superior over copper-releasing IUD for improving dysmenorrhea. The LNG-IUD is beneficial for symptom recurrence and endometriotic cyst recurrence after conservative surgery for patients with severe pain related to endometriosis. There is also evidence to support its role in menstrual problems of severely obese adolescent females. Expulsion, one of the important factors for IUD acceptability, is rare but more common in women with distorted uterine cavity. In the treatment of dysmenorrhea, the LNG-IUD is equal or superior to treat with systemic progestins or oral contraceptives even in adolescent or menopausal women.
Key words:  Intrauterine device      Dysmenorrhea      Levonorgestrel-releasing intrauterine device (LNG-IUD)      Adenomyosis      endometriosis     
Published:  10 October 2014     
*Corresponding Author(s):  A. IMAI     E-mail:  aimai@matsunami-hsp.or.jp

Cite this article: 

A. Imai, K. Matsunami, H. Takagi, S. Ichigo. Levonorgestrel-releasing intrauterine device used for dysmenorrhea: five-year literature review. Clinical and Experimental Obstetrics & Gynecology, 2014, 41(5): 495-498.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog17042014     OR     https://ceog.imrpress.com/EN/Y2014/V41/I5/495

[1] Anjeza Xholli, Anna Biasioli, Giovanni Grandi, Angelo Cagnacci. Dienogest-based hormonal contraception induced changes in the ultrasound presentation of the uterus and menstrual pain[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1186-1192.
[2] Jian-Zhong Pan, Yan Tang, Ling Li, Xin-Yue Xu, Xiao Cheng, Yuan-Yuan Chen. “Umbilical mass”: a case of primary umbilical endometriosis and literature review[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1227-1231.
[3] Sayuli Bhide, Rebecca Flyckt, Meng Yao, Tommaso Falcone. Long-term impact of chronic pelvic pain on quality of life in women with and without endometriosis[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 851-859.
[4] Xi-Wa Zhao, Meng-Meng Zhang, Jian Zhao, Wei Zhao, Shan Kang. Correlative factors associated with the recurrence of ovarian endometriosis: a retrospective study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 962-968.
[5] Sevcan Arzu Arinkan, Hilal Serifoglu. The possible association of uterine fibroid formation with copper intrauterine device use: a cross-sectional study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 969-973.
[6] Su-Xian Zhang, Lu Wu, You-Fang Hou, Bo Yan, Shao-Yan Yang, Li-Hua Yang, Qing-Hua Zhao. Hemoperitoneum caused by bleeding of adenomyosis: a case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 444-447.
[7] Ja Young Kim, Yun Gyu Song, Chang-Woon Kim, Moon Ok Lee. Uterine artery embolization using gelatin sponge particles for symptomatic focal and diffuse adenomyosis[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 59-65.
[8] Xiao-Cen Niu, Li-Hua Zhu, Zhi-Da Qian, Li-Li Huang. Disseminated intravascular coagulation developed after suction curettage in an adenomyosis patient: a case report and literature review[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 189-193.
[9] Xiao Zhang, Ying-Ying He, Nan Jiang, Zhi-Gang Sun, Feng Yan, Cidanyangzong, Fang Long, Fang-Xin Shi, Xiao-Guang Xu, Zhen Xiao. The infiltrating ability of abdominal wall endometriosis is associated with ectopic endometrial glandular activity[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 73-78.
[10] Yan-Bing Xiao, Meng Mou, Heng-Fang Gu, Hui-Xing Li, Meng-Yuan You, Zhi-Gang Liang, Lei Han. The impact of major uterine wall resection and reconstruction of the uterus (MURU) on uterine hemodynamics and ovarian function in patients with adenomyosis: a clinical study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 132-137.
[11] Masataka Ono, Junya Kojima, Ei Hasegawa, Yotaro Takaesu, Toru Sasaki, Hirotaka Nishi. Anti-Müllerian hormone levels following laparoscopic ovarian cystectomy with subcutaneous abdominal wall lifting for ovarian endometriomas[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 91-97.
[12] D. Filipecka-Tyczka, A. Kajdy, B.P. Siekierski, M. Stańczyk, A. Rogowski, M. Rabijewski, R.B. Maksym. Deep infiltrating endometriosis as a cause of severe urogynecological complications despite invasive treatment - report of two cases from the center of endometriosis surgery[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(6): 955-960.
[13] S.Y. Song, G.W. Lee, J.B. Yang, D.E. Kim, D.B. Park, H.J. Yoo. Septic shock caused by abscess formation inside cystic adenomyosis after responsive treatment of pelvic inflammatory disease[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(6): 983-987.
[14] G. Zhu, S.J. Liu, W. Lv. Bilateral borderline ovarian cystadenoma with migration of intrauterine device to right ovary accompanied with endometrial carcinoma in situ: a case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 781-784.
[15] J.H. Check, D. Check, R. Cohen. A novel effective treatment for menière’s disease – dextroamphetamine sulfate[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 807-809.
No Suggested Reading articles found!